American academy of dermatology cardiovascular research technologies 2013 American College of Cardiology

P and T

Volumn 38, Issue 5, 2013, Pages 288-292

  Alexander, Walter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APREMILAST; CANGRELOR; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; MK 3222; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; PRASUGREL; PROPRANOLOL; TICAGRELOR; TUMOR NECROSIS FACTOR INHIBITOR; TYLOXAPOL; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGIONEUROTIC EDEMA; ASTHMA; BLEEDING; BRAIN ISCHEMIA; CAPILLARY HEMANGIOMA; CORONARY ARTERY BYPASS GRAFT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL DISEASE; HUMAN; INTERVIEW; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN PRURITUS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; URTICARIA;

EID: 84878076940     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (1)

1. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163(2):182-190.